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Abstract 
Humanized mice are immunodeficient mice engrafted with human hematopoietic stem cells that 
give rise to various lineages of human blood cells throughout the life of the animal.  This article 
reviews recent advances in the generation of humanized mice, focusing on practical 
considerations. We discuss features of different immunodeficient recipient mouse strains, 
sources of human hematopoietic stem cells, advances in expansion and genetic modification of 
hematopoietic stem cells, and techniques to modulate the cytokine environment of recipient 
mice in order to enhance reconstitution of specific human blood lineage cells. We highlight the 
opportunities created by new technologies and discuss practical considerations on how to make 
best use of the widening array of basic models for specific research applications.   
 
Introduction 
In recent years there has been an explosion of interest in reconstituting the human immune 
system in mice to create humanized mice or ‘humice’. The critical technical breakthrough was 
introduction of IL2Rγ [or the common gamma chain (γc)] ablation onto already immune 
compromised backgrounds to produce receptive recipient mice lacking endogenous T, B and 
natural killer (NK) cells (1-4). In this review we consider the steps involved in constructing 
humanized mice in these animals by injecting human hematopoietic stem cells (HSCs) to 
reconstitute a human immune system. We do not consider the more complex humanized mouse 
models where multiple tissues are implanted (for example to create a human thymic 
environment or reconstitute multiple human tissues), these sophisticated models are discussed 
by Mamoro Ito in another review in this issue. We also do not consider the models developed 
using differentiated or cancerous cells, though those using peripheral blood are reviewed by 
Brehm and Shultz elsewhere in this issue.  
 
We review recent advances in three areas of humanized mouse technology.  First, we discuss 
different strains of recipient mice and how they improve the durability or quality of the human 
graft. Second, we discuss sources of human HSCs, and methods to culture and genetically 
modify HSCs following purification. Third, we review techniques to alter the cytokine 
environment once a graft has been established.  While progress has been made in each of 
these areas they have largely been worked on in isolation. We discuss outstanding questions 
and the opportunities of combining these technologies at the end of this review. At each stage 
we summarize the literature and discuss the advantages and drawbacks of particular strategies 
based on our own and other’s experience. 
 
Selection of Mouse Strains 
The ‘modern’ humanized mouse was created in the past decade by three independent 
introductions of γc mutations into already immune compromised strains: Creating the NOD Shi-
SCID γcnull (NOG) (1), NOD ltz-SCID γc-/- (NSG) (4) and Balb/c Rag-/- γc-/- (2) mouse strains.  In a 
recent comparison of mouse strains, female NSG mice were shown to be the best recipients for 
small numbers of human HSCs, based on engraftment efficiency (5). However, when large 
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numbers of HSCs are transferred, the difference largely disappears and very robust engraftment 
can be sustained in all three strains of recipient mice.  
 
These first generation ‘modern’ humice provide an important tool to study infection by human 
pathogens, especially those that infect human blood lineage cells. They have also allowed the 
investigation of human immune responses to pathogens in a small animal model. However, in 
mouse recipients the number and diversity of human cells are still below normal human ranges. 
Additionally, studies suggest that some human cells are not fully functional in mice (6, 7). 
 
This has led to the current focus on developing new genetic models that provide a better and 
more human environment for the engraftment of HSCs and the development and function of 
their progeny. These models divide into two categories – replacing the mouse-secreted factors 
with their human counterparts and improving direct cell-cell or receptor-ligand interactions. In 
addition, further work has been done to reduce rejection of human HSCs in humanized mice. 
Soluble factors that enhance reconstitution 
Cytokines, chemokines and growth factors comprise the important families of (generally) small 
secreted proteins important for cell development, differentiation, trafficking and survival. Many of 
them have been found to exhibit significant sequence divergence between human and mouse 
and to lack functional cross-reactivity in vitro. This leads to the lack of critical human species-
specific signals that support human cell survival, development and function in mice.  The 
myeloid cell lineages are worst effected as key factors seem to be almost wholly incompatible. 
As a result Billerbeck, et al. created NSG mice transgenically expressing human stem cell factor 
(SCF), granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-3 
(NSG-SGM3). Transplantation of human CD34+ fetal liver cells into these mice led to a limited 
improvement of total human hematopoietic cell reconstitution. Although the frequencies were 
elevated, human myeloid cells were still mostly found in the bone marrow. The most notable 
improvement was an increase in the number and functions of CD4+FoxP3+ human regulatory T 
cells (8).  
 
Some other groups specifically replaced mouse cytokine genes with the corresponding human 
cytokine genes. Homozygous knock-in of the thrombopoietin (TPO) gene in Balb/c Rag2-/- γc-/- 
mice led to increased levels of reconstitution of human CD45+ cells from 40% to 80% and an 
improved ratio of myelomonocytic versus lymphoid lineage cells from 14% to 32% of human 
CD45+ cells in the bone marrow of the recipients (9). Moreover, it was also shown that human 
stem and progenitor cells were better maintained in the bone marrow of these TPO knock-in 
mice. In comparison to the improvement restricted in bone marrow in TPO knock-in mice, the 
same group also generated human GM-CSF/IL-3 knock-in mice in order to improve the 
development and function of human myeloid cells. They showed that after engraftment with 
human cord blood (CB) CD34+ cells, GM-CSF/IL-3 knock-in mice had improved human myeloid 
cell reconstitution, particularly alveolar macrophages in the lung. When challenged by influenza 
virus, the humanized mice exhibited some levels of human innate immune responses (10). 
Another group generated macrophage colony-stimulating factor (M-CSF) knock-in Balb/c Rag2-/- 
γc-/- mice for supporting monocyte/macrophage lineage development. They reported more 
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efficient differentiation and enhanced frequencies of human CD33+CD14+ 
monocytes/macrophages not only in the bone marrow but also in the spleen, peripheral blood, 
lung, liver and peritoneal cavity (11). 
Cell-cell interactions 
Given the known MHC mismatch issues with human T cell interactions in humanized mice (this 
is indeed the main reason for the complex thymic grafts carried out by many laboratories) one of 
the main areas of improvement has been in engineering mice to express human major 
histocompatibility complex (MHC) genes. HLA-A2 transgenic mice expressing the most common 
human MHC I gene (~40% allelic frequency) have been reported recently to display enhanced 
CD8 T cell function (12, 13). Recent studies report that engraftment of NSG HLA-DR4 
transgenic mice with matching human HSCs produces all subsets of immunoglobulins at levels 
found in humans and improved CD4 T cell function (14). Mice lacking the murine MHC II gene 
and transgenic for HLA-DR4 have been produced, which should eliminate the diabetogenic and 
unusual NOD I-Ag7, though as yet no report is available regarding their reconstitution with 
human HSCs (15). 
Reduced rejection 
NSG, NOG, and Balb/c Rag-/- γc-/- mice all lack T, B and NK cells, which greatly reduces their 
ability to reject grafts.  However, human cells can still be rejected by mouse macrophages. One 
significant difference between the NOD and Balb/c mouse strains is a polymorphism in SIRPα, 
allowing the NOD SIRPα to recognize human CD47 and therefore inhibit macrophage 
phagocytosis (16). The CD47-SIRPα interaction has since been shown to be critical to the 
survival of circulating HSCs and has become a major therapeutic target in hematologic cancers 
(17-19). The Flavell group addressed the drawback in the Balb/c mouse strain by humanizing 
the SIRPα and were able to demonstrate that this not only allows Balb/c mice to reconstitute to 
levels similar to that seen in NSG mice but also improves immune function (20). 
Summary 
The proliferation of strains of mice for reconstitution in recent years has made the choice of 
which strain to use difficult. Given that the field is currently in flux with the many incremental 
improvements being bred together, it is difficult to predict which strain(s) will become more 
widely adopted. However, as many of these mouse strains are not at present commercially 
available, this can limit the options. In addition, many highly modified mouse strains breed 
poorly.  The robust breeding characteristic and ease of access to NSG mice mean that for the 
time being NSG mice are still the most attractive recipients available.  If a study requires one of 
the recently added human genes care should be taken to establish that the mice breed robustly 
as this has a major impact on both the cost and timeliness with which a study can be completed. 
 
Choice of HSCs 
Humanized mouse researchers use the results of the active fields of stem cell biology and 
transplantation medicine to help select which cells to inject. In stem cell research long-term 
reconstitution of immune compromised mice has been used to define all the sources of human 
HSCs.  However, injection of large numbers of stem cells to produce well-reconstituted animals 
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is more like clinical transplantation than the delicate fractionation typical of stem cell research. 
The critical parameters for humanized mouse research are 1) the aggregate reconstitution 
potential and 2) the lack of mature T and B cells in the donor cell population that mediate graft 
versus host disease. As a result, the definitive markers of the most primitive human HSCs 
proposed in recent years (21, 22) are less important than less discriminating markers such as 
CD34 and CD133, which simply capture the bulk of the long term reconstituting activity (23-25). 
Using these markers (either singly or in combination) one can fractionate cells and make 
reproducible decisions about how many cells are needed per animal to ensure optimal 
engraftment for a particular study. The three main sources of HSCs are mobilized adult 
peripheral blood, umbilical cord blood and fetal liver. We review the pros and cons of each 
briefly here.  One decision common to all HSCs is whether to use fresh or frozen cells. In either 
case cells should be assayed directly before injection for reproducible results. In general freshly 
prepared HSCs reconstitute better as there are no losses from freeze and thaw.  Although 
freezing cells makes the timing of reconstitution easier cell viability is effected and optimizing 
freeze/thaw procedures is critical. Injection timing is particularly important when using newborn 
pups as recipients (a popular choice as fewer cells are needed to reconstitute each mouse).  
We try to use fresh cells and if this isn’t possible prefer to allow cells to recover from thawing 
overnight before injection, while precise methods vary from lab to lab it is important to be 
consistent and assess how many cells are needed to achieve good reconstitution with the 
selected protocol. 
 
Mobilized adult HSCs 
This is the most abundant source of human CD34+ HSCs but unfortunately the least effective at 
reconstituting mice. While large numbers of cells are available collecting them requires relatively 
invasive procedures such as GM-CSF mobilization followed by leukaphoresis or bone marrow 
biopsy. The quality of reconstitution varies based on donor age and other clinical factors. There 
have been relatively few studies which have used these cells to date: Shultz injected 700,000 
mobilized CD34+ cells and observed ~6% chimerism in the peripheral blood of adult NSG 
recipients (4). Matsumura and co-workers injected an average of ~1.1 million mobilized CD34+ 
cells in NOG mice and observed with an average reconstitution of ~11% in the blood (26).  
Hayakawa et al. injected 2 million CD34+ cells from adult blood achieving ~16% reconstitution in 
the peripheral blood of the recipient NSG mice with Busulfan conditioning (27). As both 
Matsumura and Hayakawa also injected CB CD34+ cells in the same studies and observed far 
better engraftment (47% and 65%, respectively), it is clear that adult HSCs engraft with lower 
efficiency than cells from younger donors.  These studies suggest that creating highly chimeric 
animals using mobilized peripheral blood stem cells is likely to be inefficient. Due to the invasive 
nature of the procedures to harvest the cells, it is difficult to justify ethically in the face of less 
invasive alternatives. One major advantage of using HSCs from adult is that it is possible with 
institutional review board oversight to use information from the medical history of patients to 
study the genetic contributions to specific diseases. While as yet no study of this type has been 
reported, this type of research is an area where physician scientists with access to patient 
cohorts can potentially use humanized mice to create specific clinically relevant models of 
disease and drug toxicity. 
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Umbilical cord blood HSCs 
Umbilical cord blood (CB) has been a major source of HSCs for the construction of humanized 
mice.  As shown by the Ito group, CB CD34+ cells have many times the reconstituting activity of 
those in adults (26). Cord blood is easy to obtain (as it is considered medical waste), though 
unlike adult samples there is no medical history that may inform a particular study. Typically, CB 
cells are purified by positive selection for a stem cell marker, typically CD34 or CD133, then 
numbers used in reconstitution are normalized by phenotype, usually CD34+, CD34+CD38- or 
CD34+CD133+ cells. A typical CB sample yields about 1 million purified CD34+ cells (with a 
range from 200,000 to 10 million). Reconstitution levels and numbers of cells injected vary from 
lab to lab and each research team must establish how many cells give optimal engraftment for 
their research. In general fewer cells are needed to reconstitute new born mice rather than 
adults. Typical reconstitutions with newborn recipients use ~100,000 CD34+ cells yielding a 50-
75% reconstitution (3, 23), with ~15-20% of these cells lacking CD38 (a marker of 
differentiation) and accounting for most of the reconstituting activity as shown by the similar 
reconstitution of ~20,000 CD34+CD38- cells to 100,000 CD34+ cells (3).  
 
While less efficient than injection of neonates, adult mice are frequently used as recipients due 
to the ease of injection of cells intravenously and the simplicity of using fresh cells (as timed 
breeding is not required). Reported levels of reconstitution again vary from lab to lab and with 
specific recipient mouse strains. Injection of 100,000 to 370,000 CB CD34+ cells yields ~10-25% 
reconstitution in the peripheral blood of NOG mice (1, 26). Injection of 2 million CB CD34+ cells 
gives rise to ~65% engraftment in the peripheral blood of NSG mice (27). One interesting recent 
result from John Dick and colleagues shows that female NSG mice reconstitute better than their 
male counterparts, especially at low cell doses, showing ~3x increases in bone marrow 
reconstitution. With the ease of consolidating and rearranging female mice (as they do not fight), 
this approach makes working with adult females particularly attractive (5). 
 
In addition, minimally purified cord blood cells were used in recent work by Shultz, Greiner and 
colleagues. Injection of this CB cell population (which only had CD3+ cells depleted) containing 
~30,000 CD34+ cells gives rise to robust engraftment (~50% chimerism in the peripheral blood) 
(13).  This technique has not been replicated to date but the presence of large supporting cell 
populations may enhance engraftment and allow greater numbers of humice to be constructed 
from each cord blood sample.  
Fetal liver HSCs 
Fetal liver is also a rich source of primitive human HSCs with high repopulating potential, though 
again there is no patient specific medical information available to guide research. While fetal 
liver is disposed of as medical waste the ethical issues associated with its use require more 
detailed IRB oversight. However it is increasingly popular due to the abundance of cells (a 
typical sample at 15 to 23 weeks of gestation yields ~80 to 280 million CD34+ cells) with similar 
per cell reconstitution potential to CB CD34+ cells.  Fetal liver has been used extensively for 
making so called ‘BLT’ mice due to the advantages of a thymic graft, an area discussed by 
Mamoru Ito in his review in this issue. Typically, injection of fetal liver HSCs is done in newborn 
mice, with engraftment potential varying from strain to strain.  Balb/c Rag-/- γc-/- mice typically 
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yield 10-50% chimerism in the peripheral blood when injected with 500,000 fetal liver CD34+ 
cells (28, 29) while a higher reconstitution (30-90% chimerism in the peripheral blood) can be 
achieved in NSG mice when injected with 100,000 fetal liver CD34+ cells according to our 
experience. If the researcher can access fetal liver it offers an attractive source of cells due to 
the large numbers of CD34+ cells obtainable from a single sample.   
Summary 
The most broadly accessible sources of human HSCs are umbilical cord blood and fetal liver, 
with mobilized adult blood both harder to obtain and generally inferior for reconstitution.  The 
growing numbers of sophisticated multi organ models are increasing the popularity of fetal 
samples as multiple tissues and/or types of stem cells can be harvested from a single donor. 
The one consistent theme is that with limited exceptions reconstitutions of newborn mice rather 
than adults have proven more efficient at establishing robust engraftment with limited HSCs.  
While this limits the procedures that can be used at the time of engraftment the gains made in 
terms of numbers of mice engrafted (and thus the size of well controlled experiment groups) 
outweigh the technical difficulties. However research supplies of all of these cell types are 
limited and a major challenge is to either increase the numbers of mice that can be made from 
each donation or identify new sources of cells by transdifferentiation or improved techniques to 
harvest cells from adult donors (where the lower reconstituting activity per cell is offset by far 
higher cell numbers). A final note is that there is considerable variation in SCID repopulating 
potential between labs depending on the cell source, handling and other criteria. Therefore, it is 
critical to begin any study by titrating cells to find the smallest number of cells that gives the 
desired degree of reconstitution. 
Expansion of HSCs  
With supplies of human HSCs limited by practical and ethical considerations, one approach is to 
expand HSCs by culturing in vitro. The work done in the field of stem cell research (where the 
same strains of mice are used for the most rigorous tests of mouse reconstitution as are used 
for humanization) as well as that of human transplantation offers a number of attractive 
strategies to expand HSCs. Numerous factors have been identified which alone or more often in 
combination support the culture and expansion of HSCs and this active field is regularly 
reviewed (30-32). 
 
It is important to consider the different goals of stem cell research, transplantation and 
humanized mouse studies when evaluating culture methods to decide which ones are best for 
making humanized mice. Studies where the primary focus of the investigators was the 
generation of humanized mice and their detailed characterization following injection of cultured 
cells are few in number.  Our group and that of Dale Greiner are the notable contributors to this 
area. While these studies include detailed analysis of the lineages of cells produced and 
reconstitution levels over the timescale used for humanized mouse studies many more studies 
have focused on stem cell culture methods. Here there are far fewer details of cell phenotype 
but valuable information can still be acquired. The critical data one needs to assess a culture 
method are the fold increase in long term SCID repopulating activity, whether reconstitution was 
multi-lineage and ideally some comparison of the lineages and proportions of cells produced. 
Many reports written for other fields lack one or more of these pieces of information. Without 
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evidence of long term in vivo repopulating activity, a culture method should be viewed with 
skepticism. 
 
We review the best culture methods reported to date below and assess their pros and cons, this 
information is summarized in table 1. These cultures are broadly divided into two categories: 
feeder free cultures and cultures where another cell type serves as a feeder layer. 
 
Feeder cell free culture 
SCF, TPO, Fms-related tyrosine kinase 3 ligand (Flt-3L) culture: This is a well established stem 
cell culture cocktail which has been characterized in humanized mouse research by the Greiner 
lab who cultured HSCs and injected 1 million CD34+ cells into adult NSG recipients. The 
peripheral blood chimerism of ~4% was fairly low given the number of cells injected following 
culture although the reported 36 fold increase in CD34+ cells indicates this chimerism was 
achieved with ~30,000 input CD34+ cells.  However, the most interesting point was that they 
saw more robust myeloid reconstitution than usually found in humanized mice and less 
lymphoid reconstitution (33). 
 
Angiopoietin culture: Culturing human HSCs with angiopoietin-like proteins in combination with 
SCF, TPO, FGF and IGFBP2 gives an ~20x increase in SCID repopulating activity (measured 
rigorously by limiting dilution) and results in a robust multi-lineage engraftment which gives 30-
60% chimerism in the blood in adult NSG mice with 250,000-500,000 CD34+CD133+ cultured 
cells. It also results in the efficient reconstitution of neonate NSG mice (23, 34, 35). This 
combination of factors results in no particular bias in the cell types produced as reconstituted 
mice have very similar proportions of cells to those seen with uncultured HSCs. A complete 
characterization can be found in our recent publication (23). 
 
StemReginin culture: Recent reports that the aryl hydrocarbon antagonist StemReginin 1 (SR1) 
can enhance HSC culture are of great interest – the chemical is easy to synthesize and a great 
deal cheaper than the high concentrations of cytokines used to culture HSCs to date.  However, 
it has only been shown to work in the presence of large amounts of cytokines and seems to 
have no activity alone (36, 37).  The ~16x increase in cell numbers in culture is comparable to 
that seen with angiopoietin like proteins but as yet the resultant cultured cells have not been 
characterized in nearly as much details as the cells from the angiopoietin cultures. 
 
Notch ligand culture: Immobilized engineered notch ligand Delta1ext-Ig has been shown by 
Delaney and co-workers to be a potent enhancer of HSC expansion in culture and has been 
further shown to have significant benefits in reducing the period of neutropenia following 
transplantation in humans (38). While the clinical benefits of culture demonstrated here are of 
great importance the loss of cultured cells over time and the relatively low fold increase in SCID 
repopulating cells in long term mouse assays (~6x) means that the culture condition is at 
present not as promising as SR1 or angiopoietin-like 5. However, there is further work indicating 
that this is a potentially promising area of research as pleiotrophin has been shown by Himburg 
and co-workers to expand both human and mouse HSCs through PI3 kinase and notch 
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mediated pathways, although the expansion of human cells was not quantified or extensively 
characterized in vivo (39).  
 
Summary: The existing feeder free culture techniques offer several ways to reach a 10-20 fold 
increase in SCID repopulating activity. However, to date no effort has been made to combine 
and optimize the existing distinct cocktails to produce the best culture conditions. It is unknown 
whether these culture conditions will prove to be additive or even synergistic. Given the 
relatively superficial (for humanized mouse research) analysis performed on SR1 the easiest 
culture methods to use without extensive extra characterization are the angiopoietin-like 5 and 
FLT-3L cultures. The work of Greiner and co-workers has made the cell polarizing effects of 
FLT-3L quite clear and offer strong evidence that this factor (which was identified as a stem cell 
expansion factor using NOD/SCID mice which do not have good lymphoid reconstitution (32)) is 
in fact a myeloid growth and differentiation factor, making its introduction into cultures attractive 
if the study of myeloid cells is the end goal. The main advantage of myeloid growth factors can 
be realized either by introducing them into the mouse after reconstitution or doing so in the 
germ-line (as discussed elsewhere in this review). This leaves the angiopoietin-like 5 culture as 
both the most effective (20x expansion) and the most fully characterized of the cultures to date. 
The one caveat with this culture is that angiopoietin-like 5 production is challenging and it 
suffers from batch and vendor to vendor variation in biological activity, care should be taken to 
assay each batch in house as at present expansion of human HSCs is not tested by any vendor. 
Co-culture 
The other technique used in HSC expansion is co-culture with mesenchymal stem cells (MSCs) 
where very large increases in CD34+ cell numbers have been reported, especially with 
sophisticated 3D culture techniques. However, the main issue with these culture methods from 
the perspective of humanized mouse research is that the resultant cells are rarely injected into 
mice and long-term characterization is even rarer. While some pre-clinical work from the Shpall 
lab has shown promising results their focus has been neutropenia. They have shown only 
modest expansion of long term SCID repopulating activity and have directed their efforts 
towards rapidly producing neutrophils and platelets following engraftment (40). 
 
One paper where MSC co-culture is characterized for humanized mouse work is our study of 
MSCs and angiopoietin-like 5 (34) where we characterized the cells produced in great detail and 
were able to demonstrate an ~60x increase in the SCID repopulating cell numbers. The 
resultant mice demonstrated a T cell bias in their reconstitutions that results in a superior T cell 
dependent immune response both in terms of antibody titer and reactive T cells to tetanus 
toxoid. Taken together these data represent the most effective expansion of HSCs to date albeit 
with a polarization of the cells, which we are presently investigating.  For specific studies where 
a T cell bias is desirable – such as the very active HIV research community – this should prove 
advantageous. For many other labs where T cell activity is a neutral issue this offers an 
attractive way forward.  However, the technical difficulty of maintaining low passage MSCs for 
co-culture means that this culture method requires more expertise to run routinely than many 
other culture methods reported to date. 
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Summary 
HSC cultures developed primarily for stem cell research have offered several extremely 
attractive methods to increase long term SCID repopulating cell numbers and allow a 
commensurate increase in the number of mice that can be made from a single sample.  We can, 
with culture, routinely make large groups of adult mice from a single cord blood sample. For 
most research purposes the feeder cell free cultures with their reduced technical difficulty and 
lack of cell polarizing effects offer the most attractive way forward with angiopoietin-like 5 culture 
(~20x expansion) offering the most attractive culture described to date. If enhanced T cell 
activity is desirable the extra work of doing MSC cultures is offset by a further modest ~3x 
increase in CD34+ cell numbers (~60x total). One final advantage of an effective culture method 
is that the time spent in vitro allows transduction of the HSCs with lentiviral or retroviral vectors 
to make genetically modified human leukocytes for comparative studies analogous to the use of 
knockout and transgenic mice. 
 
Table 1: Summary of the different HSC culture methods characterized in humice to date 
Method Fold increase Notes Ref 
SCF/TPO/FLT-3L ~3x/21 days Myeloid bias (33) 
SCF/TPO/FGF/ 
IGFBP2/Angptl5 
~20x/10days Angiopoietin-like 5 needs to be assayed in 
house. 
(23) 
SCF/TPO/IL6/SR1 ~15x/21 days SR1 culture cells poorly characterized in 
humice to date. 
(36) 
SCF/FLT-3L/ 
IL6/TPO/Delta1 
~6x/21 days Expanded cells do not engraft long term in 
competition with uncultured cells in the clinic. 
(38) 
SCF/TPO/FGF/ 
IGFBP2/MSC-
Angptl5 
~60x/10 days T cell bias (34) 
 
Genetic Modification of HSCs 
HSC transduction is an active multi-disciplinary area of research and a full review of this field is 
beyond the scope of this article. While important work has been done recently in the area of in 
vivo transduction (41) and a great deal of active research has studied the transduction of all 
lineages of cells in both mouse and human, we have focused on the transduction of human 
HSCs which are then assayed in vivo in humanized mice. We have not reviewed the detailed 
protocols required to produce virus and transduce HSCs, which are a topic for an entire 
dedicated review. Instead, we focus on two key decisions – the choice of viral vector system 
and promoter selection and consider their effects on downstream studies.  
 
One of the major barriers to HSC based models is the lack of a robust protocol for selecting 
transduced HSCs, while work has been done with puromycin selection of cultured cells (42), a 
rigorous assessment of the maintenance of long term HSC activity has not been undertaken. 
Until a robust protocol is developed transduction is limited to the ~50% infection rates reported 
in the literature to date as higher doses of virus tend to kill HSCs. In some systems, this can be 
an advantage as the transduced population can be compared to internal control populations. In 
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situations where the presence of wild type cells will interfere with discerning the expected 
phenotype, a method of isolating transduced cells is necessary. 
Choice of viral vector system 
In order to mediate long term gene expression in vivo there are broadly three choices of viral 
vector systems: adeno-associated viral vectors (AAV), retroviral vectors and lentiviral vectors. 
 
Adeno-associated viral vectors (AAV): There have been controversies in the efficiency of AAV 
mediated transfection of human HSCs. It has been reported that AAV2-mediated transgene 
expression in CD34+ cells is transient, presumably because of inefficient integration (43). 
Several groups have shown successful transduction of human CD34+ HSCs by recombinant 
AAV2 vectors (44-48). Paz et al. recently demonstrated that recombinant AAV2 vector 
integrated more efficiently in the more quiescent sub-populations of human CD34+ HSCs (49). 
Most interestingly for humanized mouse studies, Santat et al. have documented successful 
transduction of primitive human CD34+ HSCs capable of serial engraftment in NOD/SCID mice 
(46). With the availability of several serotypes, rational design of capsid mutants, and strategies 
(self-complementary vector genomes, hematopoietic cell-specific promoters), it is becoming 
feasible to achieve efficient transduction of human HSCs by AAV vectors (50). 
 
Retroviral vectors: These vectors are replication defective viral vectors derived from the gamma-
retroviruses. They require a dividing cell to successfully infect and generally mediate constitutive 
gene expression from the viral long terminal repeat (LTR). Retroviral vectors have two major 
problems for long term HSC work: First, they tend to be silenced over time especially as cells 
differentiate to produce committed progeny. Second, they tend to disrupt gene expression and 
have intrinsic oncogenic potential, which was illustrated by the IL2Rγ gene therapy clinical trials 
where the retroviral integration was in almost identical areas of the genome in the cancers of 
multiple patients (51-54). However, if the objective of a study is to induce hematologic 
malignancies this can actually be an advantage as demonstrated by the Dick group in their work 
to retrovirally induce acute leukemia using MLL-ENL (55). 
 
Lentiviral vectors: Lentiviral vectors derived from HIV-1 are now the favored gene therapy vector 
with a combination of desirable features – LTRs which do not drive gene expression (56), no 
direct link to cancer (57), the ability to infect non-dividing cells (58) and (especially after 
engineering) good resistance to gene silencing (59). Given this combination of features and the 
extensive work that has been undertaken in producing safe efficient lentiviral vectors, these are 
currently the preferred type of vector for long-term transduction of HSCs. 
Summary: The advances made in the field of gene therapy are often directly applicable to 
humanized mouse studies and the growing consensus is that integrating viral vectors based on 
onco-retroviruses pose significant risks, self-inactivating lentiviral vectors based on HIV are the 
best available technology from the standpoint of safety and utility. 
Promoters 
In addition to the selection of an appropriate viral vector the choice of promoter is key to shaping 
a transduced HSC project. There are now a broad range of promoters which have been 
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characterized in sufficient detail to identify compact functional regions small enough to fit into a 
lentiviral vector (space is limited as the genome is not efficiently packaged once it gets much 
above 10kb in length). We briefly review the various promoters available highlighting good 
promoter choices for different applications. While there are many lentiviral vectors, we focus on 
those that have been tested to date in humanized mice following HSC transduction. 
 
Constitutive promoters: Constitutive promoters are the most widely used in lentiviral vectors.  
However, for HSC transduction they have two important limitations – firstly all lineages of cells 
derived from the HSCs will express the transduced gene and secondly expression of extra 
genes in HSCs can often result in loss of self renewal and thus loss of the transduced HSC 
engraftment over time. Table 2 lists broadly available promoters that have been tested in HSCs 
in humanized mice. These promoters are best used for projects where several lineages of cells 
need to be transduced or where events early in hematopoiesis are under consideration. 
 
T cell-specific promoters: Several T cell specific promoters have been indentified over the years 
and used in transfection studies and to create transgenic mice. The best characterized is the 
CD4 proximal promoter with or without the proximal repressor, which supports pan T cell or CD4 
restricted gene expression, though there is some leakage in other lineages (60). 
 
B cell-specific promoters: Several B cell specific promoters have been developed, however the 
best characterized of these in humanized mice are from the Tonelle group – who developed a 
combined CD19 promoter and Eµ enhancer (61, 62). The Rawlin’s laboratory has described 
lentiviral vectors that also use the Eµ enhancer with either CD19 or Igβ (B29) promoters (63). 
While the B29 promoter seems to mediate stronger expression of GFP than the CD19 promoter 
both are reported to be leaky in the Rawlin’s vectors. The Tonelle vectors on the other hand 
shows very low leakage and a much lower level of expression in cells of other lineages (62). 
This makes it the first choice for B cell specific expression to date. 
 
Myeloid cell-specific promoter: Myeloid specific promoters that have been used to date in 
humanized mice have targeted specific subsets of myeloid cells. An HLA-DR specific promoter 
has been characterized in NOD SCID mice as a way of transducing human antigen presenting 
cells in humanized mice (64). Platelet specific promoter integrin αIIb has been shown to be 
active in human CD34+ derived megakaryocytes and specifically expressed in mouse 
megakaryocytes and platelets following transduction of mouse HSCs (65, 66). The β-globin 
promoter has been described in similar detail as a potential gene therapy for sickle cell anemia 
and β-thalassemia, where progenitor cells were allowed to develop in mouse xenografts and 
used to repair a ‘humanized’ mouse genetic model of sickle-cell anemia (67, 68). While other 
promoters have been described they have not been used in humanized mice. 
 
In conjunction with HSC culture, transduction of HSCs allows a powerful tool to be deployed to 
study the molecular mechanisms underlying human immunity and disease. While relatively few 
promoters have been extensively characterized in human HSCs in mice there are reasonably 
characterized promoters available to study many of the major lineages of cells as detailed in 
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Table 2. This is an approach that has not been extensively employed in humanized mice and 
represents an excellent opportunity to explore human biology.  
 
Table 2: Summary of lentiviral vector promoters used in humanized mice 
Promoter Expression Tested in 
humice 
Notes Ref 
UCOE Ubiquitous No Also promotes chromatin opening  and 
inhibits gene silencing 
(69) 
UBC Ubiquitous Yes Constitutive long term expression in 
NOD SCID mice 
(70) 
WAS Ubiquitous Yes Constitutive long term expression in 
NOD SCID mice 
(70) 
PGK Ubiquitous Yes  (60) 
CD4 proximal Pan T/CD4 Yes Expression depends on presence of CD8 
repressor elements – some leakage in 
NK and myeloid cells 
(60) 
Eµ/CD19 B Cell Yes Low leakage strong specific expression (61, 62) 
B29 B Cell Yes Higher leakage than Eµ/CD19 (63) 
HLA-DR APC Yes Expression tested in NOD SCID mice (64) 
β globin RBC No Tests carried out in mouse HSCs and 
human RBC progenitors allowed to 
develop in humanized mice 
(67, 68) 
Integrin αIIb Platelet No Expression specificity demonstrated in 
mouse post HSC transduction not in 
human to date 
(65, 66) 
CD68 Macrophage No Expression specificity has been 
established in human cells for the 150bp 
proximal promoter and tested lentivirally 
in vivo in mice. 
(71, 72) 
 
Cytokine Administration in Reconstituted Animals 
Once humanized mice have been generated experimentation can begin. For many studies it is 
desirable to further manipulate the system either by immunization/pathogen infection or by 
direct molecular stimulation. One of the easiest ways to do this is to alter the cytokine and/or 
growth factor environment to promote expansion and/or activation of particular subsets of 
human cells. 
 
Indeed many of the new transgenic models discussed earlier were based on the results of 
cytokine administrations that demonstrably improved engraftment. As a result this tool is now 
being increasingly used to test hypotheses by perturbing existing models as well as to screen 
for factors that enhance humanization. This is achieved either by directly injecting human 
soluble factors or by hydrodynamic DNA injection, which induces expression of plasmid-
encoded cytokines by the mouse liver. We briefly discuss the range of soluble factors 
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administered to date and the phenotypes they induce, summarizing all the collected data in 
Table 3. 
Injection of soluble factors  
In the early stages of humanized mouse development SCID mice were injected with various 
growth factors to enhance engraftment. The extremely low peripheral reconstitution level of the 
time (0.7% on average) (73, 74) was improved by injection of human IL-3 (increasing 
engraftment to ~4%) (75, 76). IL-2, IL-7, Flt-3L and SCF were shown to have no activity 
individually. 
 
Co-treatment with erythropoietin (EPO), SCF, and/or GM-CSF/IL-3 fusion protein in adult 
human BM-transplanted SCID mice enhanced the proportion of human cells from <1% to 10-
15% in treated animals, with development of multiple hematological cell lineages (77). However, 
treatment with human IL-3, GM-CSF and mast cell growth factor (MGF) had no effect on SCID 
mice engrafted with CB cells where higher levels (~15%) of engraftment could be achieved 
without treatment (78). This suggested that the CB cells respond differently to the murine 
microenvironment and/or GM-CSF and IL-3, possibly secreting key factors in a paracrine 
fashion. Based on the observations of improved engraftment after infusion of cytokines (75-77) 
and the relative bias toward B cell differentiation in several SCID mouse models, it has been 
confirmed that murine GM-CSF, M-CSF, IL-3, and TPO are not cross-reactive with human cells, 
whereas Flt-3L, IL-7 (which support lymphoid differentiation), and SCF are cross-reactive, at 
least to some extent.  
 
With more permissive mouse models such as NOD/SCID, high levels of human cell engraftment 
were seen (11%-81% human CD45+ cells in BM) (79).  However, this tended to mask any effect 
of injected human cytokines such as IL-3, GM-CSF and EPO which showed little effect on 
hematopoiesis in this model (80). Only in less permissive strains such as C57BL/6 Rag2-/- γc-/- 
mice where CB engraftment resulted in <1% human CD45+ cells in the bone marrow could any 
effect be seen. Treatment of these mice with a mixture of IL-3, GM-CSF, and EPO showed 
limited improvement of human engraftment to ~18% human CD45+ cells in the bone marrow 
(80). These observations demonstrate an important point – it is only in situations of limited 
engraftment that the beneficial effects of human cytokines are generally seen.  
 
With the subsequent development of NOG and NSG mice, robust human cell engraftment is no 
longer a major problem. However, humanized mouse models still required further improvement 
For the following two reasons. First, the reconstitution of human NK cells and myeloid cells is 
generally poor (6, 81). Second, despite the capacity to support human B and T cell development 
from transplanted human HSCs, humanized mice have shown poor adaptive responses (7, 82, 
83). Researchers thus focused on the improvement of reconstitution and function of specific 
human cell populations in humanized mouse models. Human NK cell reconstitution was 
intrinsically low in humanized mouse models because of the poor cross-reactivity of mouse IL-
15. Kalberer et al. showed that a 1-week-long persistent in vivo treatment with various 
combinations of IL-15, Flt-3L, SCF, IL-2, IL-12 and megakaryocyte growth and differentiation 
factor (MGDF) could improve human NK cell development (from ~0.3% to ~5% in the spleen 
and bone marrow within the human CD45+ cell population) in NOD/SCID mice injected with CB 
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CD34+ cells (81). Similarly, in BALB/c Rag2-/-γc-/- mice engrafted with fetal liver HSCs, the 
frequencies of human CD56+ NKp46+ NK cells in all the lymphoid organs were very low (from 
0.3% to 1.5% within human CD45+ cell population) (84). Administration of a hIL-15/IL-15Rα 
complex increased NK cell numbers by 1.5 to 3 fold in all the lymphoid organs (84). This NK cell 
induction has been proposed as a means to assess antibody dependent cellular cytotoxicity in 
NSG mice reconstituted with CB CD34+ cells (85). Most recently, Pek et al. also confirmed that 
administration of recombinant human IL-15 or an adenoviral vector expressing IL-15 are able to 
significantly enhance human NK cell development and maturation, particularly in the bone 
marrow and liver (86).  
 
Limited de novo human thymopoiesis and peripheral T cell accumulation is a common feature of 
several humanized mouse models (4, 84, 87). Senpuku et al. showed that IL-18 treatment could 
stimulate the engraftment and migration of human CD4+ and CD8+ T cells in NOD/SCID mice 
transplanted with human peripheral blood lymphoid cells (88). Shultz et al. showed that 
administration of human Fc-IL-7 fusion protein results in dramatic increases in human 
CD4+CD8+ thymocytes and peripheral blood and splenic human T cells in NSG mice 
transplanted with mobilized adult CD34+ cells (4). Similarly, it was demonstrated that treatment 
of human recombinant IL-7 showed transient effects on human thymopoiesis and plasmacytoid 
dendritic cells (pDC) development in young humanized Rag2-/-γc-/- mice (<10 week-old) 
engrafted with CD34+ cells purified from human fetal livers without affecting peripheral T cell 
homeostasis (87). Recently, Huntington et al. reported that administration of human IL-15 
boosts the numbers of both CD4+ and CD8+ T cells in the periphery and enhances B cell 
responses by increasing the frequency of antigen-specific responses following immunization 
(89). 
  
Human myeloid and erythroid cells have also been induced in mice. When stromal cells 
secreting human EPO and IL-3 were co-transplanted into bone marrow with CD34+ human 
HSCs in beige/nude/XID (bnx) mice, detectable levels of human red blood cells were transiently 
produced with an increase in hematocrit from 40% to 80% (75). A recent publication also 
confirmed that EPO and IL-3 treatment could further improve the peripheral human RBCs levels 
in humanized NOD/SCID and NOD/SCID/γc-/- mice (90). These results show that GM-CSF, M-
CSF and IL-3 are critical for human myeloid cell development in mice due to their high species-
specific activities, but EPO shows cross-reactivity as mouse red blood cells also expand. 
Expression of Human Cytokines by Injecting DNA Plasmids 
Single injections of recombinant human cytokines in mice only produce a transient effect 
(typically 2 to 3 days). Repeated injections of large amounts of human cytokines are costly and 
labor intensive. To overcome these difficulties we developed hydrodynamic-tail-vein injection of 
DNA plasmids encoding cytokines in CB or fetal liver CD34+ cell-engrafted NSG mice (6). This 
simple, inexpensive and efficient method allows the expression of flexible combinations of 
human cytokines in vivo for a long period (2-3 weeks for most of cytokines) following a single 
injection. We have tested several cytokines and combinations as detailed below. 
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We showed that the combination of IL-15 and Flt-3L expression dramatically improves the 
reconstitution and functions of human NK cells in both hematopoietic and non-hematopoietic 
tissues.  NK cell frequencies were increased 3 to 10 fold depending on the organ examined, and 
absolute numbers of NK cells per tissue also increased 5 to 10 fold. These cells were functional 
showing enhanced responses to in vivo virus challenge (6).  
 
After injecting plasmids expressing human GM-CSF, IL-4 and Flt-3L, we detected human 
CD209+ DCs in blood, spleen, bone marrow, lung and livers. These DCs were hardly detected 
in untreated humice, yet they represented ~5% of human leukocytes after hydrodynamic 
injection. When an M-CSF plasmid was injected, the proportion of human macrophages 
increased by a factor of 10 to 20 in the tissues. These cytokine induced macrophages are 
functional because only the M-CSF treated humanized mice could exhibit significant in vivo 
macrophage responses when challenged by H1N1 flu or BCG (Tuberculosis) vaccine compared 
to non-treated humanized mice (unpublished data). Finally, when a combination of EPO and IL-
3 plasmids were injected, human red blood cells (RBCs) were significantly induced in the 
peripheral blood, from below detection to a level of 1-4% in total RBCs (6). These results 
demonstrate that hydrodynamic injection offers opportunities for rapid testing of human 
cytokines and other genetically-encoded soluble molecules in humanized mice. 
Summary 
There are a significant number of human cytokines and growth factors that have been induced 
in humice (summarized in Table 3). To date the majority have caused expansion of cell subsets 
with the best results being seen when their target (whether whole graft or a particular subset) is 
poorly reconstituted in the starting model. Going forward a major focus of these sorts of short-
term induction/injection studies will be modulating the function of specific human cell types. 
 
Hydrodynamic-tail-vein-injection based cytokine expression shows certain advantages: 1) 
relatively long expression time courses (2-3 weeks per injection), 2) the expression level of each 
of several cytokines can be controlled by adjusting the dose of corresponding DNA plasmids 
used, and 3) low cost. This makes the strategy extremely useful for the rapid assessment of the 
systemic effects of particular soluble factors in humice. 
 
Future Directions 
This review has focused on research improving humanized mouse models, notably by creating 
new mouse strains and techniques to manipulate the human graft either directly (lentiviral 
infection) or indirectly (treatment with human soluble proteins). In addition a great deal of work 
has been done generating and characterizing infectious disease models in humice and creating 
models with additional human tissues, notably liver and thymus. 
 
Going forward, three areas will likely attract significant effort: 
 
Firstly, using the new tools available in conjunction with human infections which have until now 
lacked a small animal model. This will lead to new biological insights and allow the assessment 
of potential new therapies. The HIV research community, which has already produced over 100 
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research papers using humanized mice is leading by example. In this and other disease areas 
such as dengue, malaria and EBV infection all the tools are in place to test hypotheses about 
cell intrinsic factors (by using lentiviral vectors) and environmental effects of cytokines and 
growth factors by using hydrodynamic injection, new mouse strains and injection of recombinant 
proteins. 
 
Secondly, the new technologies detailed in this review will allow an unprecedented chance to 
determine the genetic and environmental causes of autoimmune disease and hematologic 
cancer. By perturbing gene expression with lentiviral vectors and altering the ‘normal’ 
environment by introducing new combinations of human cytokines it will be possible to generate 
new disease models and in the process learn which factors are critical drivers of disease for 
human cells in vivo. This should serve as a powerful counterpoint to the sophisticated purely 
murine models currently in use as well as providing a timely platform to test biologics in vivo 
ahead of clinical trials. 
 
Finally, the improvements seen in the last few years will be refined and integrated to make 
vastly better humanized mouse models.  Already mouse strains with multiple knock-ins, knock-
outs and transgenes are being characterized and the race is on to develop a mouse which 
combines all the advances in the myeloid and lymphoid lineages, reconstitution and cell function.  
As mice with fully functional human T, B, NK, macrophage and dendritic cells become available 
the focus will shift to generating mice with functional human neutrophils as well as the rarer 
granulocyte subsets and NK T cells. 
 
In conclusion the work of the last five years has set the scene for what should be an explosion 
of biological insights and an increasingly prominent place in pre-clinical trials for humanized 
mice as they finally come of age over the next few years. 
 
 
Table 3. Effect of human cytokines on human cells in various strains of humanized mice 
Cytokine treatment Method Notes Ref 
IL-3 Injection Enhances engraftment (75, 76) 
EPO,SCF,GM-
CSF/IL-3 
Injection Enhances engraftment (77) 
IL-3,GM-CSF,EPO Injection Enhanced engraftment in the bone marrow (78, 80) 
IL-15,FL,SCF,IL-2,IL-
12,MGDF 
Injection Enhances NK cell engraftment (81) 
hIL15/IL-15Rα Injection Enhances NK cells and T Cells (84) 
IL-18 Injection Enhances direct T cell engraftment  (88) 
Fc-IL-7 Injection Enhances thymopoiesis and T cell engraftment (4) 
IL-7 Injection Enhances thymopoiesis and pDC development (87) 
EPO, IL-3 Injection/ 
Hdam injection 
Stimulates human RBC production (6, 75, 90) 
IL-2/IL-15 fusion +Flt-
3l 
Hdam injection Improved NK cell reconstitution (6) 
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GM-CSF + IL4 Hdam injection Improved DC reconstitution (6) 
MCSF Hdam injection Improves monocyte/macrophage reconstitution (6) 
SCF,GM-CSF,IL-3 Transgene Some myeloid improvement and more Tregs (8) 
TPO  Knock-in Improves engraftment and enhanced myeloid 
cells in the bone marrow 
(9) 
GM-CSF, IL-3 Knock-in Improved myeloid reconstitution esp. alveolar 
macrophages 
(10) 
M-CSF  Knock-in Improves monocytes/macrophage 
reconstitution in all organs. 
(11) 
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